Digest Network Come funziona
Network
/
Società
Gr
Non verificato

Grünenthal Group

Di cosa scriviamo

EconomiaFarmaceuticaFitnessSaluteSanità

14 comunicati stampa

Guarda tutti i comunicati
16/07/2026
Ecologia/Salute ambientale
Agricoltura
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
08/07/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
29/06/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
05/03/2026
Salute
Fitness
Imprese
Industria
Medicina - Varie
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
02/03/2026
Salute
Fitness
Imprese
Industria
Medicina - Varie
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
02/06/2025
Farmaceutica
Sanità
Economia
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
20/05/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Maren Thurow starts as new Head Global Communications at Grünenthal
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
24/02/2025
Farmaceutica
Banca
Sanità
Economia
Brevetti, marchi e copyright
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
09/01/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
07/11/2024
Farmaceutica
Sanità
Economia
Start-up
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0